The ReadoutBiotech’s buyout fizzle, a parent-sponsored clinical trial, & CureVac’s curious tweet By Damian Garde June 3, 2021 Reprints Alex Hogan/STAT The Readout for June 03, 2021 About the Author Reprints Damian Garde National Biotech Reporter Damian Garde covers biotech, is a co-writer of The Readout newsletter, and a co-host of "The Readout LOUD" podcast. [email protected] @damiangarde
The Readout Meghana Keshavan Regeneron targets obesity, a new microbiome deal, & comparing cancer drug costs
The Readout Damian Garde Should the feds investigate Aduhelm? Plus: biotech’s biggest binaries & regenerating heart tissue
The Readout Damian Garde Docs disagree with FDA on Aduhelm, Swiss giants pinch pennies, & one SPAC makes it rain
The Readout Damian Garde How Biogen got Aduhelm approved, Sanofi’s future in mRNA, & Celgene’s endless saga
The Readout Meghana Keshavan Aduhelm’s impact on Medicare, a new CRISPR therapy, & a Warp Speed retirement
